Pharmacy groups, the generic drug lobby and other stakeholders are urging the Senate Special Committee on Aging to file its own version of a House bill designed to stop brand-name drug companies from using restricted access programs to block generic drug market entry. The groups say brand-name drug manufacturers' use of Risk Evaluation and Mitigation Strategies to block generic manufacturers from obtaining samples of brand drugs costs the health care system more than $5 billion a year, in a letter...